{"id":4437,"date":"2019-03-14T14:32:50","date_gmt":"2019-03-14T09:02:50","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=4437"},"modified":"2021-07-24T12:57:15","modified_gmt":"2021-07-24T07:27:15","slug":"the-business-cocktail-58","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-58","title":{"rendered":"BioNTech lines up $800M; Deerfield remunerates; Britain&#8217;s Smith &#038; Nephew to acquire Osiris"},"content":{"rendered":"\n<p class=\"has-background has-pale-cyan-blue-background-color\"><strong>BioNTech\nlines up USD 800 Million for fuelling mRNA R&amp;D<\/strong><\/p>\n\n\n\n<p><strong>BioNTech <\/strong>is lining up a <strong>Nasdaq IPO <\/strong>that raises <strong>USD 800 million<\/strong>. The German <strong>mRNA <\/strong>specialist is contemplating to stimulate its cash-intensive plans. BioNTech has booked <strong>Bank of America and JPMorgan<\/strong> with a plan to list on Nasdaq. The current plan is to increase to USD 800 million at a valuation of USD 4 billion. <\/p>\n\n\n\n<p class=\"has-background has-pale-cyan-blue-background-color\"><strong>Deerfield\nremunerates USD 100 Million for research of translational agreement <\/strong><\/p>\n\n\n\n<p><strong>Deerfield Management and Harvard University<\/strong> are collaborating on translational <strong>R&amp;D <\/strong>to pave the way to the clinic for new therapies discovered at Harvard. The duo is establishing a new company named as <strong>Lab1636<\/strong>, with USD 100 million in backing from Deerfield. The new company will be wholly retained by the affiliates of Deerfield and will bolster Harvard R&amp;D projects at various stages of drug discovery and development. <\/p>\n\n\n\n<p class=\"has-background has-pale-cyan-blue-background-color\"><strong>Britain&#8217;s\nSmith &amp; Nephew to acquire Osiris in regenerative products push<\/strong><\/p>\n\n\n\n<p><strong>Smith &amp; Nephew<\/strong> has moved further to absorb regenerative medicine developer <strong>Osiris Therapeutics<\/strong> in a USD 660 million agreement. This way, the company hopes will extend and speed up its wound care business. The portfolio of Osiris includes bone graft, cartilage and skin substitutes that include its main growth drivers &#8211; <strong>Grafix and Stravix<\/strong>. It accounted for more than 70% of the company\u2019s sales in the first nine months of 2018. They both were derived from cryopreserved placental tissues. Grafix is planned to replace skin after being directly applied to deep acute and chronic wounds. Whereas, Stravix is used as a surgical wrap to bolster soft <strong>tissue repairs<\/strong> in a range of procedures. <\/p>\n","protected":false},"excerpt":{"rendered":"<p>BioNTech lines up USD 800 Million for fuelling mRNA R&amp;D BioNTech is lining up a Nasdaq IPO that raises USD 800 million. The German mRNA specialist is contemplating to stimulate its cash-intensive plans. BioNTech has booked Bank of America and JPMorgan with a plan to list on Nasdaq. The current plan is to increase to [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4397,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[1287,17694,2822,2826],"industry":[17225],"therapeutic_areas":[17235,17278],"class_list":["post-4437","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-biontech","tag-grafix-and-stravix","tag-osiris-therapeutics","tag-tissue-repairs","industry-pharmaceutical","therapeutic_areas-cell-and-gene-therapy","therapeutic_areas-other-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>BioNTech lines up $800M; Deerfield remunerates; Smith &amp; Nephew acquire<\/title>\n<meta name=\"description\" content=\"BioNTech is lining up a Nasdaq IPO that raises USD 800 million. The German mRNA specialist is contemplating to stimulate its cash-intensive plans...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-58\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BioNTech lines up $800M; Deerfield remunerates; Smith &amp; Nephew acquire\" \/>\n<meta property=\"og:description\" content=\"BioNTech is lining up a Nasdaq IPO that raises USD 800 million. The German mRNA specialist is contemplating to stimulate its cash-intensive plans...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-58\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-03-14T09:02:50+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/03\/09023607\/Untitled-Project.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1598\" \/>\n\t<meta property=\"og:image:height\" content=\"1339\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"BioNTech lines up $800M; Deerfield remunerates; Smith & Nephew acquire","description":"BioNTech is lining up a Nasdaq IPO that raises USD 800 million. The German mRNA specialist is contemplating to stimulate its cash-intensive plans...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-58","og_locale":"en_US","og_type":"article","og_title":"BioNTech lines up $800M; Deerfield remunerates; Smith & Nephew acquire","og_description":"BioNTech is lining up a Nasdaq IPO that raises USD 800 million. The German mRNA specialist is contemplating to stimulate its cash-intensive plans...","og_url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-58","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-03-14T09:02:50+00:00","article_modified_time":"2021-07-24T07:27:15+00:00","og_image":[{"width":1598,"height":1339,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/03\/09023607\/Untitled-Project.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-58","url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-58","name":"BioNTech lines up $800M; Deerfield remunerates; Smith & Nephew acquire","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-58#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-58#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/03\/09023607\/Untitled-Project.png","datePublished":"2019-03-14T09:02:50+00:00","dateModified":"2021-07-24T07:27:15+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"BioNTech is lining up a Nasdaq IPO that raises USD 800 million. The German mRNA specialist is contemplating to stimulate its cash-intensive plans...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-58"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-58#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/03\/09023607\/Untitled-Project.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/03\/09023607\/Untitled-Project.png","width":1598,"height":1339,"caption":"mRNA"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/03\/09023607\/Untitled-Project-300x251.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">BioNTech<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Grafix and Stravix<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Osiris Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">tissue repairs<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">BioNTech<\/span>","<span class=\"advgb-post-tax-term\">Grafix and Stravix<\/span>","<span class=\"advgb-post-tax-term\">Osiris Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">tissue repairs<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Mar 14, 2019","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Mar 14, 2019 2:32 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/4437","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=4437"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/4437\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/4397"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=4437"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=4437"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=4437"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=4437"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=4437"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}